Show results for
Refine by
Clinical Proof Equipment & Supplies In Finland
13 equipment items found
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
K-NK003: A phase 1 study evaluating NK cells as a treatment for patients with relapse and refractory acute myeloid leukemia (AML). This study was designed based on promising clinical proof-of-concept data from two studies, one at MD Anderson Cancer Center and one at HCPA in ...
Manufactured by:Vivesto AB based inSolna, SWEDEN
Cantrixil is a product candidate in clinical stage being developed for the treatment of ovarian cancer. Cantrixil consists of the active molecule, a potent and selective third generation benzopyran SMETI inhibitor named TRXE-002-01, encapsulated in a cyclodextrin. It is believed to target a wide spectrum of cancer cells, including chemotherapy-resistant tumor-initiating cells ...
Manufactured by:Kiadis Pharma NV based inAmsterdam, NETHERLANDS
K-NK002: A phase 2 clinical study evaluating haplo-identical NK cells to prevent post-transplant relapse in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). This study was designed based on promising clinical proof-of-concept data from MD Anderson Cancer Center. The phase 2 trial for K-NK002 will be conducted in ...
by:CuraVac Europe S.A. based inRixensart, BELGIUM
The MYASTERIX project (2013 – 2018) advanced a Therapeutic Vaccine candidate (designated orphan drug) indicated for myasthenia gravis (MG) to clinical proof of concept ...
by:AdAlta Limited based inBundoora, AUSTRALIA
Under the Collaboration Agreement, AdAlta will discover and optimise panels of i-bodies that bind to designated solid tumour antigen targets, from which Carina will generate CAR-T cells and identify optimal CAR-T product candidates including bi-specific CAR-T products. Carina and AdAlta will jointly fund pre-clinical proof of concept studies in mouse tumour ...
Manufactured by:CyberKnife, by Accuray Incorporated based inMadison, WISCONSIN (USA)
CyberKnife treatments are typically performed in 1 to 5 sessions. The CyberKnife System has more than two decades of clinical proof and has helped thousands of cancer ...
Manufactured by:Futura Medical based inGuildford, UNITED KINGDOM
Scientific advisory meeting held with MHRA confirming the need of a Phase 3 study to support the improved skin permeation including potential superior efficacy claims. Exploring the feasibility of a clinical study to satisfy the Phase 3 requirements for both UK and US approval. Development currently on ...
by:STALICLA based inGeneve, SWITZERLAND
STALICLA’s precision medicine approach begins with ‘endophenotyping’-identifying the nonbehavioral physical and molecular presentations of NDDs and characterizing subgroups of patients with similar disease signatures. DEPI matches these patient subgroups with an NDD-targeted drug (or drug combination) by integrating and analyzing large omics data sets, including genomics, ...
by:Blueback Physio based inPacé, FRANCE
As often in entrepreneurship, the idea of BlueBack was born from a personal story. The story of a young woman who at the age of twenty, was forbidden to practice sports because of back pain. After a long medical journey (specialized doctor, specialized rehabilitation center...), the real cause of the pathology is not treatable unless the resumption of a regular physical activity with as a ...
Manufactured by:Vaxcyte, Inc. based inSan Carlos, CALIFORNIA (USA)
We believe our clinical-stage company is uniquely positioned to create vaccines that can overcome bacteria’s formidable defense mechanisms and be produced on a significant scale. We are leveraging our XpressCF™ cell-free protein synthesis platform to create high-fidelity vaccines featuring distinct protein carriers and antigens – the critical building blocks of vaccines ...
Manufactured by:EsoCap AG based inBasel, SWITZERLAND
EsoCap owns a unique drug delivery platform allowing the topical application of drug substances for targeted and long-lasting treatment of diseases of the upper gastrointestinal tract for the first ...
Manufactured by:Lattice Medical based inLoos, FRANCE
Lattice Medical is a biomedical start-up that was launched in October 2017; Patented 3D technology developed with CHU Lille-France that allows adipose tissue to naturally ...
Manufactured by:Ascelia Pharma AB based inMalmö, SWEDEN
Oncoral is a novel daily irinotecan chemotherapy in development. Irinotecan chemotherapy has an established potent anti-tumor effect – even in difficult to treat cancers. Oncoral is a daily irinotecan tablet with the potential to offer better patient outcomes with improved safety following the daily dosing at home compared to intravenous high-dose infusions at the hospital. Following ...